These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35233616)

  • 1. Improving Pneumococcal Vaccination Rates in High-risk Children in Specialty Clinics.
    Harris JG; Harris LA; Olarte L; Elson EC; Moran R; Blowey DL; El Feghaly RE
    Pediatrics; 2022 Apr; 149(4):. PubMed ID: 35233616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jun; 62(25):521-4. PubMed ID: 23803961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
    ;
    MMWR Morb Mortal Wkly Rep; 2010 Sep; 59(34):1102-6. PubMed ID: 20814406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Pneumococcal Vaccination in Pediatric Rheumatology Patients.
    Harris JG; Maletta KI; Ren B; Olson JC
    Pediatrics; 2015 Sep; 136(3):e681-6. PubMed ID: 26304825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older.
    Kawakami K; Nakamura A; Wakana A; Folaranmi TA; Iino T
    Hum Vaccin Immunother; 2020 Jul; 16(7):1521-1528. PubMed ID: 31799889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years.
    Black CL; Williams WW; Warnock R; Pilishvili T; Kim D; Kelman JA
    MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(27):728-733. PubMed ID: 28704347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017.
    Shimbashi R; Suzuki M; Chang B; Watanabe H; Tanabe Y; Kuronuma K; Oshima K; Maruyama T; Takeda H; Kasahara K; Fujita J; Nishi J; Kubota T; Tanaka-Taya K; Matsui T; Sunagawa T; Oishi K;
    Emerg Infect Dis; 2020 Oct; 26(10):2378-2386. PubMed ID: 32946721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
    Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
    Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Pneumococcal Vaccination Rates in Rheumatology Patients by Using Best Practice Alerts in the Electronic Health Records.
    Sheth HS; Grimes VD; Rudge D; Ayers B; Moreland LW; Fischer GS; Aggarwal R
    J Rheumatol; 2021 Sep; 48(9):1472-1479. PubMed ID: 33323531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease.
    Yildirim I; Shea KM; Little BA; Silverio AL; Pelton SI;
    Pediatrics; 2015 Mar; 135(3):495-503. PubMed ID: 25647674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Pneumococcal Vaccination Rates in Cochlear Implant Programs: A Systematic Review and Meta-analysis.
    Britt AF; Poupore NS; Nguyen SA; White DR
    Otolaryngol Head Neck Surg; 2023 Mar; 168(3):291-299. PubMed ID: 35852861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A quality improvement intervention failed to significantly increase pneumococcal and influenza vaccination rates in immunosuppressed inflammatory arthritis patients.
    Murray K; Low C; O'Rourke A; Young F; Callanan I; Feeney E; Veale DJ
    Clin Rheumatol; 2020 Mar; 39(3):747-754. PubMed ID: 31820135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions-United States.
    Ahmed SS; Pondo T; Xing W; McGee L; Farley M; Schaffner W; Thomas A; Reingold A; Harrison LH; Lynfield R; Rowlands J; Bennett N; Petit S; Barnes M; Smelser C; Beall B; Whitney CG; Pilishvili T
    Clin Infect Dis; 2020 Jun; 70(12):2484-2492. PubMed ID: 31402387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature.
    Cripps AW; Folaranmi T; Johnson KD; Musey L; Niederman MS; Buchwald UK
    Expert Rev Vaccines; 2021 Mar; 20(3):257-267. PubMed ID: 33567914
    [No Abstract]   [Full Text] [Related]  

  • 18. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence.
    Niederman MS; Folaranmi T; Buchwald UK; Musey L; Cripps AW; Johnson KD
    Expert Rev Vaccines; 2021 Mar; 20(3):243-256. PubMed ID: 33478306
    [No Abstract]   [Full Text] [Related]  

  • 20. An initiative to improve pneumococcal immunization counseling in children with nephrotic syndrome.
    Sandokji I; Anderson LS; Warejko JK; Emerson BL; Greenberg JH
    Pediatr Nephrol; 2022 Jun; 37(6):1333-1338. PubMed ID: 34734331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.